The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9334502 B1

PDF
Full Text
Expired
Date of Patent:
May. 10, 2016

Filed:

Jan. 18, 2012
Applicants:

Haixiong Han, Shanghai, CN;

Xiangying Zhu, Shanghai, CN;

Qin Sun, Shanghai, CN;

Xuefeng Gu, Shanghai, CN;

Shenghua Xie, Shanghai, CN;

Yang LI, Shanghai, CN;

Yangsheng Jin, Shanghai, CN;

Honghua Qu, Shanghai, CN;

Yueqiong Cao, Shanghai, CN;

Inventors:

Haixiong Han, Shanghai, CN;

Xiangying Zhu, Shanghai, CN;

Qin Sun, Shanghai, CN;

Xuefeng Gu, Shanghai, CN;

Shenghua Xie, Shanghai, CN;

Yang Li, Shanghai, CN;

Yangsheng Jin, Shanghai, CN;

Honghua Qu, Shanghai, CN;

Yueqiong Cao, Shanghai, CN;

Assignee:

SHANGHAI GENECHEM CO., LTD, Pudong District, Shanghai, CN;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); C12N 2310/11 (2013.01); C12N 2310/12 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2799/027 (2013.01); C12Y 207/11 (2013.01);
Abstract

The present invention discloses the use of a human NLK gene and associated drugs thereof. The present invention discloses the use of the NLK gene for tumor treatment, tumor diagnosis and drug preparation. The present invention further constructs an isolated molecule that attenuates expression of the NLK gene of tumor cells, cells comprising the isolated molecule and a NLK interference lentivirus, and discloses the use thereof as well. The isolated molecule or the NLK interference lentivirus that attenuates expression of the NLK gene provided in the present invention can specifically attenuate expression of the human NLK gene, especially the lentivirus, can effectively infect target cells, efficiently inhibit the expression of the NLK gene in target cells, and inhibit the growth of tumor cells, thus has great significance in tumor treatment.


Find Patent Forward Citations

Han, Haixiong. (2016). Use of human nlk gene and associated drugs thereof (U.S. Patent No. 9334502). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9334502

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…